LifeMD, Inc. LFMD

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company’s 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on October 15, 2026, to holders of record at the close of business on October 2, 2026. About LifeMD, Inc. LifeMD® is a le

LifeMD, Inc. (NASDAQ:LFMD) announced an exclusive healthcare collaboration on September 15 that initially makes virtual-health membership benefits available to approximately 29 million eligible AT&T wireless and fiber customers across 11 states. Customers must be 18 or older, and some services have additional eligibility and state restrictions. A nationwide expansion planned for January 2027 would extend […]

AT&T is branching beyond its usual telecom offerings with a benefit that could catch some customers off guard.

AT&T (NYSE:T) has introduced Cricket 5G Home Internet, extending fixed wireless broadband over its existing 5G network for Cricket Wireless customers. The telecom group has partnered with LifeMD to provide eligible AT&T subscribers with free virtual healthcare visits and related telehealth services. Through these moves, AT&T is widening its bundled connectivity offer by adding home broadband and healthcare benefits to its consumer plans. Cricket 5G Home Internet and the LifeMD virtual care...

LifeMD is back in focus after fair value in the updated model shifted from US$9.88 to US$8.13, an adjustment of about 18% that aligns with lower Street price targets in recent research. Analysts have been resetting expectations following the latest Q2 report and guidance, with some still pointing to long term growth drivers while acknowledging nearer term pressure on revenue and earnings outlooks. In the sections that follow, you will see how this evolving narrative around LifeMD might shape...

Moby summary of LifeMD, Inc.'s Q2 2026 earnings call

LifeMD (LFMD) delivered earnings and revenue surprises of +20.00% and -3.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from comp

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.Gross margin expanded approximately 280 basis p

Medifast (NYSE:MED) reported second-quarter 2026 revenue of $76.4 million, down 27.6% from a year earlier, as its active earning coach base continued to decline amid the rapid adoption of GLP-1 medications across the traditional weight-loss category. The company posted a net loss of $3.1 million, or

NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and six months ended June 30, 2026, after the close of the U.S. financial markets on August 5, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Wednesday, August 5thTime:4:30 p.m. Eastern timeToll-Free Dial-In:(800) 715-9871International Dial-In:+

Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing arrangement with LifeMD for the XYOSTED self-pay program, launching in July 2026 in 37 states Companies to collaborate on consumer education and promotional initiatives to expand awareness of hypogonadism and convenient, transparent access to FDA-approved treatment NEW YORK and SAN DIEGO, June 22, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a lead

LifeMD’s latest analyst update comes with no change to the current price target, keeping expectations steady for now. Even without fresh commentary, the unchanged target still sends a signal about how analysts are holding their view. Looking ahead, you will see how to track these kinds of shifts so you can stay in step with the evolving LifeMD story. Stay updated as the Fair Value for LifeMD shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover...